{
    "clinical_study": {
        "@rank": "87500", 
        "acronym": "PUL", 
        "arm_group": [
            {
                "arm_group_label": "Group A", 
                "arm_group_type": "Experimental", 
                "description": "Group A - Treatments 1, 2, 3 and 4: Dysport 16 Units (U)/kg in one upper extremity (the study limb)."
            }, 
            {
                "arm_group_label": "Group B", 
                "arm_group_type": "Experimental", 
                "description": "Group B - Treatments 1, 2, 3 and 4: Dysport 8 U/kg in one upper extremity (the study limb)."
            }, 
            {
                "arm_group_label": "Group C", 
                "arm_group_type": "Experimental", 
                "description": "Group C - Treatment 1: Dysport 2 U/kg in one upper extremity (the study limb).\nGroup C - Treatments 2, 3 and 4: Dysport 8 or 16 U/kg in one upper extremity (the study limb)."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to assess the efficacy and safety of multiple doses of Dysport\n      used in the treatment of upper limb spasticity (altered skeletal muscle performance) in\n      children with cerebral palsy (CP)."
        }, 
        "brief_title": "Efficacy And Safety Of Dysport In The Treatment Of Upper Limb Spasticity In Children", 
        "completion_date": {
            "#text": "June 2018", 
            "@type": "Anticipated"
        }, 
        "condition": "Upper Limb Spasticity (Altered Skeletal Muscle Performance) in Children", 
        "condition_browse": {
            "mesh_term": "Muscle Spasticity"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Upper limb spasticity due to cerebral palsy\n\n          -  Body weight 10 kg or over\n\n          -  MAS score of 2 or more in affected elbow or wrist flexors\n\n        Exclusion Criteria:\n\n          -  Fixed myocontracture\n\n          -  Previous phenol or alcohol injection within 1 year\n\n          -  Severe athetoid or dystonic movements\n\n          -  Previous or planned surgery in elbow or wrist flexors\n\n          -  Neuromuscular disorders\n\n          -  Rhizotomy within 6 months\n\n          -  Intrathecal baclofen within 30 days"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "17 Years", 
            "minimum_age": "2 Years"
        }, 
        "enrollment": {
            "#text": "210", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02106351", 
            "org_study_id": "Y-52-52120-153"
        }, 
        "intervention": {
            "arm_group_label": [
                "Group A", 
                "Group B", 
                "Group C"
            ], 
            "description": "Subjects randomised to receive Dysport 2 U/kg, 8 U/kg or 16 U/kg administered intramuscularly in the study limb.", 
            "intervention_name": "AbobotulinumtoxinA Dysport\u00ae", 
            "intervention_type": "Drug", 
            "other_name": "Dysport\u00ae"
        }, 
        "intervention_browse": {
            "mesh_term": "Botulinum Toxins, Type A"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 7, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas"
                }
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase III, Multicentre, Double Blind, Prospective, Randomised, Controlled, Multiple Treatment Study Assessing Efficacy And Safety Of DYSPORT\u00ae Used In The Treatment Of Upper Limb Spasticity In Children", 
        "overall_contact": {
            "email": "clinical.trials@ipsen.com", 
            "last_name": "Ipsen Recruitment Enquiries"
        }, 
        "overall_official": {
            "affiliation": "Ipsen", 
            "last_name": "Medical Director, Neurology", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "August 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The MAS is a 6-point scale which measures the amount of muscle tone by measuring the resistance of the muscle to passive lengthening or stretching. Score on MAS range from 0 (no increase in tone) to 4 (affected part(s) rigid in flexion or extension).", 
            "measure": "Mean change from baseline in the Primary Targeted Muscle Group on Modified Ashworth Scale (MAS)", 
            "safety_issue": "No", 
            "time_frame": "Baseline and Week 6 (Treatment 1)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02106351"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "PGA of treatment response assessed on a 9-point rating scale. Score on PGA scale range from -4 (markedly worse) to +4 (markedly improved).", 
                "measure": "Mean Physician's Global Assessment (PGA) score of the Treatment Response", 
                "safety_issue": "No", 
                "time_frame": "Week 6 (Treatment 1)"
            }, 
            {
                "description": "The GAS is a functional 5-point scale used to measure progress towards individual therapy goals. Individual goals defined for each subject by the Investigator and the child's parents/guardians/caregivers prior to treatment. Score on GAS range from +2 (Much more than expected outcome) to -2 (Much less than expected outcome).", 
                "measure": "Mean Goal Attainment Scale (GAS) score", 
                "safety_issue": "No", 
                "time_frame": "Week 6 (Treatment 1)"
            }
        ], 
        "source": "Ipsen", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Ipsen", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}